Role of ARB in hypertensive patients with metabolic syndrome and chronic heart failure - Telmisartan vs Olmesartan

Therapeutic Research

Volumn 28, Issue 6, 2007, Pages 1175-1182

  Noda, Yoshiki ^a   Sasaki, Tatsuya ^a   Hamaoka, Mamoru ^b  

^a MINAMI OSAKA GENERAL HOSPITAL   (Japan)

^b OSAKA KOSEI NENKIN HOSPITAL   (Japan)

Author keywords

ARB; Home based blood pressure; Metabolic syndrome

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLMESARTAN; TELMISARTAN;

ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART FAILURE; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; SYSTOLIC BLOOD PRESSURE;

EID: 34547111073     PISSN: 02898020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Japanese source
2. Kakuta H, et al. Telmisartan has the strongest binding affinity to Angiotensin II type 1 receptor : Comparison with other Angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005;25:41-6.
3. Japanese source
4. Chrysant SG, et al. Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases : focus on telmisartan. J Hum Hypertens 2005;19:173-83.
5. Lacourciere Y, et al. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Pressure Monitering 2004;9:203-10.
6. Williams B, et al. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens 2006;24:193-200.
7. Benson SC, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR γ -modulating activity. Hypertension 2004;43:993-1002.
8. Shimabukuro M, et al. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens 2007;25:841-8.
9. Ther Res 2003;24:505-12.
10. Bobrie G, et al. Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004;291:1342-9.
11. http://www.mhlw.go.jp/houdou/2006/05/h0508-1a.html
12. Japanese source
13. Pershadsingh HA, et al. Insulin-sensitizing effects of telmisartan implications for treating insulin-resistant hypertension and cardiovascular disease. Diabetes Care 2004;27:1015.
14. Schupp M, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 2004;109:2054-7.
15. Vitale C, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005;4:6.
16. Honjo S, et al. Possible beneficial effect of telmisartan on glycemic control in diabetic subjects. Diabetes Care 2005;28:498.
17. Miura Y, et al. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes : metabolic and antiatherogenic consequences. Diabetes Care 2005;28:757-8.
18. Sugimoto K, et al. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006;47:1003-9.
19. Fujimoto M, et al. An angiotensin II AT I receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Letter 2004;576:492-7.
20. Derosa G, et al. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients : a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004;27:457-64.
21. Derosa G, et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension : a 12-month, randomized, double. Clin Ther 2004;26:1228-36.
22. ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients : The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANCEND) trials. Am Heart J 2004;148:52-61.